Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres











Base de données
Gamme d'année
1.
AAPS PharmSciTech ; 25(7): 212, 2024 Sep 07.
Article de Anglais | MEDLINE | ID: mdl-39242428

RÉSUMÉ

UV radiation causes long- and short-term skin damage, such as erythema and skin cancer. Therefore, the use of sunscreens is extremely important. However, concerns about UV filter safety have prompted exploration into alternative solutions, with nanotechnology emerging as a promising avenue. This systematic review identified 23 experimental studies utilizing nanocarriers to encapsulate sunscreens with the aim of enhancing their efficacy and safety. Polymeric and lipid nanoparticles are frequently employed to encapsulate both organic and inorganic UV filters along with natural antioxidants. Nanocarriers have demonstrated benefits including reduced active ingredient usage, increased sun protection factor, and mitigated photoinstability. Notably, they also decreased the skin absorption of UV filters. In summary, nanocarriers represent a viable strategy for improving sunscreen formulations, offering enhanced physicochemical properties and bolstered photoprotective effects, thereby addressing concerns regarding UV filter safety and efficacy in cosmetic applications.


Sujet(s)
Nanoparticules , Nanotechnologie , Produits antisolaires , Rayons ultraviolets , Animaux , Humains , Antioxydants/administration et posologie , Antioxydants/composition chimique , Antioxydants/pharmacologie , Vecteurs de médicaments/composition chimique , Lipides/composition chimique , Nanoparticules/composition chimique , Nanotechnologie/méthodes , Polymères/composition chimique , Peau/métabolisme , Peau/effets des médicaments et des substances chimiques , Absorption cutanée/effets des médicaments et des substances chimiques , Indice de protection solaire , Produits antisolaires/composition chimique , Produits antisolaires/administration et posologie , Rayons ultraviolets/effets indésirables
2.
Crit Rev Ther Drug Carrier Syst ; 41(6): 57-88, 2024.
Article de Anglais | MEDLINE | ID: mdl-38804554

RÉSUMÉ

Major depressive disorder is considered one of the most common and prevalent diseases worldwide, affecting children, adults, and the elderly. Currently, several antidepressant drugs are available on the market, but the low adherence of patients due to the slow therapeutic response is a problem to be solved. In this way, cyclodextrins become an alternative to circumvent the limitations and improve the physicochemical and pharmacological properties of this class of drugs. Thus, the objective of this work is to carry out a current review of patents associating antidepressant drugs and cyclodextrins. The patent search was performed in two patent databases, the World Intellectual Property Organization and the European Patent Office using terms in the title and abstract fields and the international patent classification code for antidepressant drugs. In the end, 27 patent documents were selected and divided into three classifications, physical-chemical characterization study, pre-clinical in vivo trials, and clinical trials. The scientific evidence found in the patents considers the use of cyclodextrins as an important alternative to improve the therapeutic and physicochemical properties of antidepressant drugs, among the main improved properties are, solubility, stability, masking taste and odor, bioavailability.


Sujet(s)
Antidépresseurs , Cyclodextrines , Brevets comme sujet , Antidépresseurs/composition chimique , Antidépresseurs/pharmacologie , Antidépresseurs/administration et posologie , Cyclodextrines/composition chimique , Humains , Animaux , Solubilité , Trouble dépressif majeur/traitement médicamenteux , Biodisponibilité , Stabilité de médicament
3.
Expert Rev Med Devices ; 21(1-2): 91-107, 2024.
Article de Anglais | MEDLINE | ID: mdl-38189146

RÉSUMÉ

INTRODUCTION: Osteoarthritis is a musculoskeletal disease that can lead to the loss and inability of those affected to perform normal daily functions, which leads to a decrease in quality of life. The main symptoms of osteoarthritis are tenderness, joint pain, stiffness, crepitus, limited movement, and local inflammation. AREAS COVERED: The selected patents were deposited from 2010 to April 2022 involving 57 documents that were in line with the study objective in the final selection. The patents were classified in years, country, and applicants. Also, the therapeutic fields that presented the most documents were electrical stimulation, phototherapy, and ultrasound, followed by magnetic, electromagnetic, and thermotherapy. Therefore, the most current therapies used in the documents are already on the market. EXPERT OPINION: Although the OA is cureless, non-surgical treatments are classified as the primary management approach for this disease. The pharmacological and non-pharmacological therapies are employed to reduce its prevalence and ensure the effectiveness of treatments. A strategy for relieving OA symptoms is non-pharmacological treatment, which can be based on exercise and patient education, combined with other alternative therapies. These therapies are used as supplements to the main OA treatments, enhancing the effectiveness of treatment outcomes.


Sujet(s)
Hyperthermie provoquée , Arthrose , Humains , Qualité de vie , Arthrose/thérapie , Inflammation , Exercice physique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE